Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

587 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.
Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB; German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group. Siebert U, et al. Gut. 2003 Mar;52(3):425-32. doi: 10.1136/gut.52.3.425. Gut. 2003. PMID: 12584228 Free PMC article. Clinical Trial.
Critical limb ischemia: hybrid MR angiography compared with DSA.
Meissner OA, Rieger J, Weber C, Siebert U, Steckmeier B, Reiser MF, Schoenberg SO. Meissner OA, et al. Among authors: siebert u. Radiology. 2005 Apr;235(1):308-18. doi: 10.1148/radiol.2343031685. Epub 2005 Feb 16. Radiology. 2005. PMID: 15716387
Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security.
Siebert U, Sroczynski G; German Hepatitis C Model GEHMO Group; HTA Expert Panel on Hepatitis C. Siebert U, et al. Int J Technol Assess Health Care. 2005 Winter;21(1):55-65. doi: 10.1017/s0266462305050075. Int J Technol Assess Health Care. 2005. PMID: 15736515 Review.
Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany.
Siebert U, Sroczynski G, Wasem J, Greiner W, Ravens-Sieberer U, Aidelsburger P, Kurth BM, Bullinger M, von der Schulenburg JM, Wong JB, Rossol S. Siebert U, et al. Eur J Health Econ. 2005 Jun;6(2):112-23. doi: 10.1007/s10198-005-0280-7. Eur J Health Econ. 2005. PMID: 15902546
Cost effectiveness of haemophilia treatment: a cross-national assessment.
Lippert B, Berger K, Berntorp E, Giangrande P, van den Berg M, Schramm W, Siebert U; European Haemophilia Economic Study Group. Lippert B, et al. Among authors: siebert u. Blood Coagul Fibrinolysis. 2005 Oct;16(7):477-85. doi: 10.1097/01.mbc.0000178830.39526.ff. Blood Coagul Fibrinolysis. 2005. PMID: 16175006
A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score.
Baggish AL, Siebert U, Lainchbury JG, Cameron R, Anwaruddin S, Chen A, Krauser DG, Tung R, Brown DF, Richards AM, Januzzi JL Jr. Baggish AL, et al. Among authors: siebert u. Am Heart J. 2006 Jan;151(1):48-54. doi: 10.1016/j.ahj.2005.02.031. Am Heart J. 2006. PMID: 16368291
587 results